Cresco Labs Announces Conference Participation for May 2022

CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE: CL) (OTCQX: CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced its executive team will participate in the following conferences in May 2022:

Canaccord Genuity Virtual Cannabis Conference, May 11, 2022: Chief Executive Officer Charles Bachtell will participate in a fireside chat with analyst Derek Dley and management will participate in one-on-one meetings.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Facebook: Cresco Labs

Instagram: Cresco Labs

Twitter: Cresco Labs

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005276/en/

Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
[email protected]

Investors:
Megan Kulick, Cresco Labs
Senior Vice President, Investor Relations
[email protected]

For general Cresco Labs inquiries:
312-929-0993
[email protected]

Source: Cresco Labs Inc.

You May Also Be Interested In

• SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results
• Rockwell Medical Announces Second Quarter 2026 Results
• Canyons School District Streamlines Procurement and Contract Management With Euna Solutions